Hutchison China MediTech Dívida/Patrimônio
Qual é o Dívida/Patrimônio de Hutchison China MediTech?
O Dívida/Patrimônio de Hutchison China MediTech Ltd. é 0.72
Qual é a definição de Dívida/Patrimônio?
O índice de endividamento é um índice financeiro que indica a proporção relativa do patrimônio líquido e da dívida usada para financiar os ativos de uma empresa.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Dívida/Patrimônio de empresas na Setor Health Care em LSE em comparação com Hutchison China MediTech
O que Hutchison China MediTech faz?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Empresas com dívida/patrimônio semelhantes a Hutchison China MediTech
- Informa Plc tem Dívida/Patrimônio de 0.72
- Ashok Alco-Chem tem Dívida/Patrimônio de 0.72
- YASKAWA Electric tem Dívida/Patrimônio de 0.72
- Warehouses De Pauw SCA tem Dívida/Patrimônio de 0.72
- Warehouses De Pauw NV tem Dívida/Patrimônio de 0.72
- CyanConnode plc tem Dívida/Patrimônio de 0.72
- Hutchison China MediTech tem Dívida/Patrimônio de 0.72
- Universal Security Instruments tem Dívida/Patrimônio de 0.72
- Zimmer Biomet Inc tem Dívida/Patrimônio de 0.72
- Oriental Trimex tem Dívida/Patrimônio de 0.72
- Buru tem Dívida/Patrimônio de 0.72
- American Homes 4 Rent tem Dívida/Patrimônio de 0.72
- Langham Hospitality Investments tem Dívida/Patrimônio de 0.72